Additional Information
Description:
The Ozempic® (semaglutide) 0.25/0.5 mg per 3 mL pen is a once-weekly GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; its mechanism of action leverages the native GLP-1 function to stimulate insulin secretion and suppress glucagon secretion in a glucose-dependent manner, thereby effectively lowering A1C with a low risk of hypoglycemia.
You've just added this product to thecart:
